ARPA-H-Funded COSMIC Team Develops Closed-Loop Tear Biosensor System for Real-Time Drug Delivery and Disease Monitoring; Faces Complex FDA Path as a Combination Product

July 12, 2026

Eye Care Network – Ophthalmology Times USA

Overview

The ARPA-H-funded COSMIC team, led by Dr. Dipanjan Pan at Penn State University, is conducting early-stage research on a closed-loop tear biosensor system. This system aims for continuous disease monitoring and real-time drug delivery, based on an electrochemical sensing architecture. The path to FDA clearance is anticipated to be complex due to its nature as a ‘combination product’ integrating sensing, software, and drug delivery in a single unit, holding potential to revolutionize ocular disease management.

In Depth

Key Findings

The ARPA-H-funded COSMIC team, led by Dr. Dipanjan Pan at Pennsylvania State University, is advancing early-stage research on a closed-loop tear biosensor system with the potential to revolutionize ocular disease diagnosis and treatment. This innovative system aims to enable continuous monitoring of disease states and responsive, real-time drug delivery, based on an advanced electrochemical sensing architecture. As a ‘combination product’ integrating sensing, software, and drug delivery capabilities into a single unit, the U.S. Food and Drug Administration (FDA) approval process is anticipated to be complex, yet its potential clinical value is considered exceptionally high.

Technical/Clinical Details

This closed-loop tear biosensor system is likely to function as a contact lens-like device, continuously detecting specific biomarkers present in tear fluid (e.g., inflammatory cytokines, molecules related to intraocular pressure, drug concentrations). Electrochemical sensors convert interactions with these biomarkers into electrical signals, which are then analyzed by an embedded microprocessor. Based on the analysis, the software evaluates disease progression or drug response and, if necessary, activates a drug delivery module. The drug delivery module is designed to release precise amounts of medication (e.g., glaucoma medication or anti-inflammatory drugs) directly into the tear fluid, potentially adjusting the dosage according to the disease state. This system aims to maximize therapeutic efficacy and minimize side effects by automatically delivering the appropriate amount of medication at the right time, rather than relying on manual patient administration of eye drops. For instance, in glaucoma patients, continuous monitoring of intraocular pressure and automated delivery of pressure-lowering agents could theoretically become possible.

Background and Industry Context

Ocular diseases, particularly chronic conditions such as glaucoma and age-related macular degeneration, require continuous monitoring and strict medication management. However, challenges include low patient compliance and the need for frequent administration of conventional eye drops. Furthermore, disease progression is often slow and asymptomatic, making early detection and continuous monitoring critically important. Traditional diagnostic tools often provide limited information only during periodic clinic visits, making it difficult to capture dynamic changes in disease. The closed-loop tear biosensor system holds the potential to address these challenges, reduce patient burden, and provide more effective and personalized treatment. Funding from organizations like ARPA-H (Advanced Research Projects Agency for Health) is crucial for accelerating the research and development of such high-risk, high-reward innovative medical technologies.

Strategic Significance & Outlook

This closed-loop tear biosensor system holds the potential to redefine the future of ocular disease management. In the future, it is expected to become a standard for diagnosis, monitoring, and treatment across various ocular conditions, including retinal diseases, glaucoma, and dry eye syndrome. While the FDA approval process is complex, clear guidelines for such ‘combination products’ could accelerate market entry. If this technology becomes widespread, patients will enjoy a higher quality of life, and healthcare providers will be able to offer more efficient and precise care. Ultimately, it is expected to significantly reduce the risk of vision loss due to ocular diseases and play a critical role in preserving vision worldwide.

Source: https://www.ophthalmologytimes.com/view/dipanjan-pan-early-stage-tear-biosensor-research-closed-loop-drug-delivery-fda-clearance

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.